2seventy, Bristol Myers
✕About this result- This title and these news articles are related to your search term(s).
- Articles come from a variety of sources across the web.
- Titles are algorithmically generated based on content related to your search term(s).
- People also ask
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB5 days ago — CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol …
News Releases - 2seventy bio
WEBMay 3, 2024 — U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of …
Struggling 2Seventy scraps a key cancer study | BioPharma Dive
WEB5 days ago — The decision announced Wednesday was made, in part, to help ensure 2Seventy breaks even financially next year. The biotechnology company expects ending …
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB5 days ago — 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment …
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB5 days ago — 2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study. Decision results in over $80 million in anticipated cost savings for …
2seventy bio Provides Update on KarMMa-9 Study and Previews
WEB5 days ago — About 2seventy bio. Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of …
2seventy bio Announces New Strategic Path Forward
WEBJan 30, 2024 — CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jan. 30, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus …
2seventy bio Announces Strategic Restructuring to Prioritize …
WEBSep 12, 2023 — 2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway. September …
2seventy bio Completes Spin Transaction and Launches Innovative …
WEBNov 4, 2021 — 2seventy bio, Inc., (NASDAQ: TSVT), an emerging immuno-oncology company today announced its official launch as an independent, publicly traded company.
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBJan 30, 2024 — An estimated 150 employees from 2seventy bio will transition to Regeneron to continue their work on cell therapy programs and will remain located in Cambridge, …
- Some results have been removed
